ArticleFrontiers in endocrinology2026
A lightweight DeepME model based on improved YOLOv11 architecture for macular edema detection and treatment monitoring.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We developed and validated an improved YOLOv11-based deep learning algorithm for accurate macular edema detection in optical coherence tomography (OCT) images, and built DeepME-a lightweight system for diagnosis and treatment recommendations. Methods: We compiled a comprehensive dataset combining hospital clinical data and public OCT resources, covering macular edema and other retinal diseases. External validation used an anti-vascular endothelial growth factor (anti-VEGF) cohort of 336 eyes from 300 patients with diabetic retinopathy or retinal vein occlusion. The improved YOLOv11n integrated the Convolutional Block Attention Module (CBAM) to enhance feature extraction. DeepME combined this detector with an optimized DeepSeek model, current clinical guidelines, and expert knowledge. Results: DeepME achieved better performance over standard YOLOv11: accuracy 0.980, specificity 0.990, sensitivity 0.970, precision 0.990, F1-score 0.980, and AUC 0.9993. Grad-CAM visualizations confirmed precise localization of cystoid macular edema within anatomically correct retinal layers. In the anti-VEGF cohort, central foveal thickness decreased significantly at one-month follow-up (p < 0.001), and DeepME showed substantial agreement with manual grading (p < 0.001), enabling rapid, accurate diagnosis and treatment guidance. Conclusion: This study introduces DeepME, a novel clinical decision support system that integrates an improved YOLOv11 detection architecture for comprehensive macular edema management. DeepME delivers high accuracy in evaluating anti-VEGF treatment response and shows strong potential for real-world clinical decision support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.